|
EP2593561A1
|
|
Methods and kits for the diagnosis of prostate cancer
|
|
EP2535711A1
|
|
Diagnostic marker for acute coronary syndrome
|
|
WO2011148027A1
|
|
Tracking and traceability method and system for use in the production and administration of medical preparations
|
|
EP2503340A1
|
|
Diagnostic marker for relapsing primary idiopathic focal segmental glomerulosclerosis
|
|
EP2474621A1
|
|
Markers for selecting personalised cancer treatment therapies
|
|
EP2407555A1
|
|
Methods and kits for the diagnosis of prostate cancer
|
|
ES2372506A1
|
|
METHOD OF DETECTION OF SUSCEPTIBILITY TO DEVELOP ADVERSE SIDE EFFECTS RELATED TO BIOIMPLANTS.
|
|
ES2344289A1
|
|
GENE CONSTRUCTION THAT UNDERSTANDS THE GENE THAT CODIFIES THE GENETICALLY MODIFIED KAPY ANIMAL PROTEIN WITH THE SAME.
|
